AbbVie | ABBV

Stock Price
159.39
Daily Change
-3.59 -2.20%
Monthly
-5.95%
Yearly
11.84%
Q2 Forecast
162.62
Peers Price Chg Day Year Date
Eisai 6,640.00 47.00 0.71% -22.88% May/23
AbbVie 159.39 -3.59 -2.20% 11.84% May/22
Abbott 104.82 1.70 1.65% -0.87% May/22
ALKERMES 24.21 -0.13 -0.53% -18.70% May/22
Amgen 309.28 -5.54 -1.76% 37.80% May/22
AstraZeneca 12,412.00 52.00 0.42% 5.24% May/23
Biogen 225.04 -2.53 -1.11% -25.77% May/22
BioMarin Pharmaceutical 76.45 -0.89 -1.15% -16.89% May/22
Bristol-Myers Squibb 42.33 0.04 0.09% -36.37% May/22
Gilead Sciences 67.74 0.43 0.64% -13.79% May/22
GlaxoSmithKline 1,795.50 7.00 0.39% 27.45% May/23
J&J 153.43 2.14 1.41% -2.16% May/22
Eli Lilly 802.19 -1.60 -0.20% 89.55% May/22
Medtronic 85.75 0.56 0.66% -1.58% May/22
Merck 131.09 0.39 0.30% 15.73% May/22
Neurocrine Biosciences 139.43 -1.12 -0.80% 48.90% May/22
Novartis 93.20 0.04 0.04% 2.88% May/23
Pacira 30.72 -0.18 -0.58% -26.01% May/22
Pfizer 29.59 1.00 3.50% -25.35% May/22
Perrigo 29.31 -0.38 -1.28% -11.47% May/22
Ultragenyx Pharmaceutical 41.08 0.50 1.23% -20.11% May/22
Regeneron Pharmaceuticals 984.09 -10.36 -1.04% 31.46% May/22
Roche Holding 233.65 1.75 0.75% -19.10% May/23
Sanofi 91.30 0.50 0.55% -9.50% May/23
UCB 129.00 1.40 1.10% 52.92% May/23
United Therapeutics 276.44 1.25 0.45% 27.87% May/22
Vertex Pharmaceuticals 447.66 6.91 1.57% 34.23% May/22
Zoetis 171.90 -0.97 -0.56% -0.45% May/22

Indexes Price Day Year Date
US500 5348 -14.41 -0.27% 29.96% May/23

AbbVie traded at $159.39 this Wednesday May 22nd, decreasing $3.59 or 2.20 percent since the previous trading session. Looking back, over the last four weeks, AbbVie lost 5.95 percent. Over the last 12 months, its price rose by 11.84 percent. Looking ahead, we forecast AbbVie to be priced at 162.62 by the end of this quarter and at 157.93 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.